Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:rifaximin
go back to main search page
Accession:CHEBI:75246 term browser browse the term
Definition:A semisynthetic member of the class of rifamycins and non-systemic gastrointestinal site-specific broad spectrum antibiotic. Used in the treatment of traveller's diarrhoea, hepatic encephalopathy and irritable bowel syndrome.
Synonyms:exact_synonym: (2S,16Z,18E,20S,21S,22R,23R,24R,25S,26R,27S,28E)-5,6,21,23-tetrahydroxy-27-methoxy-2,4,11,16,20,22,24,26-octamethyl-1,15-dioxo-1,2-dihydro-2,7-(epoxypentadeca[1,11,13]trienoimino)furo[2'',3'':7',8']naphtho[1',2':4,5]imidazo[1,2-a]pyridin-25-yl acetate
 related_synonym: Formula=C43H51N3O11;   InChI=1S/C43H51N3O11/c1-19-14-16-46-28(18-19)44-32-29-30-37(50)25(7)40-31(29)41(52)43(9,57-40)55-17-15-27(54-10)22(4)39(56-26(8)47)24(6)36(49)23(5)35(48)20(2)12-11-13-21(3)42(53)45-33(34(32)46)38(30)51/h11-18,20,22-24,27,35-36,39,48-51H,1-10H3,(H,45,53)/b12-11+,17-15+,21-13-/t20-,22+,23+,24+,27-,35-,36+,39+,43-/m0/s1;   InChIKey=NZCRJKRKKOLAOJ-XRCRFVBUSA-N;   Rifamycin L 105;   Rifamycin L 105SV;   Rifaxidin;   SMILES=CO[C@H]1\\C=C\\O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(NC(=O)\\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c1c(nc5cc(C)ccn15)c4c3C2=O;   Xifaxsan;   rifaximina;   rifaximine;   rifaximinun
 xref: CAS:80621-81-4;   DrugBank:DB01220;   Drug_Central:2379;   HMDB:HMDB0015351;   KEGG:D02554
 xref_mesh: MESH:C042734
 xref: PMID:23092785;   PMID:23095030;   PMID:23183443;   PMID:23216382;   PMID:23273888;   PMID:23274384;   PMID:23275147;   PMID:23303506;   PMID:23314671;   PMID:23340064;   PMID:23389621;   PMID:23445237;   PMID:23526308;   PMID:23556126;   PMID:23565181;   PMID:23589147;   PMID:23640348;   PMID:23653636;   PMID:23740443;   PMID:23798671;   PMID:23843564;   PMID:23877348;   PMID:23922656;   PMID:25214516;   PMID:25339518;   PMID:25565769;   PMID:25586470;   PMID:25641072;   PMID:25835116;   PMID:25867912;   PMID:25932262;   PMID:26028929;   PMID:26043290;   Reaxys:7790802;   Wikipedia:Rifaximin


show annotations for term's descendants           Sort by:
 
rifaximin term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcb1a ATP-binding cassette, sub-family B (MDR/TAP), member 1A multiple interactions
increases expression
ISO [NR1I2 results in increased susceptibility to rifaximin] which results in increased expression of ABCB1A mRNA
rifaximin results in increased expression of ABCB1 mRNA
CTD PMID:21141967 PMID:22790967 NCBI chr 5:8,567,091...8,748,575
Ensembl chr 5:8,660,077...8,748,575
JBrowse link
G Acta2 actin, alpha 2, smooth muscle, aorta multiple interactions ISO [NR1I2 results in increased susceptibility to rifaximin] which results in increased expression of ACTA2 mRNA CTD PMID:22790967 NCBI chr19:34,240,336...34,255,585
Ensembl chr19:34,241,090...34,255,590
JBrowse link
G Apoa4 apolipoprotein A-IV multiple interactions ISO [NR1I2 results in increased susceptibility to rifaximin] which results in increased expression of APOA4 mRNA CTD PMID:22790967 NCBI chr 9:46,240,844...46,243,458
Ensembl chr 9:46,240,696...46,243,459
JBrowse link
G Ccl3 chemokine (C-C motif) ligand 3 multiple interactions EXP [rifaximin binds to and results in increased activity of NR1I2 protein] inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of CCL3 protein]; rifaximin inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of CCL3 protein] CTD PMID:21599020 NCBI chr11:83,647,843...83,649,378
Ensembl chr11:83,647,844...83,649,355
JBrowse link
G Cd36 CD36 molecule multiple interactions ISO [NR1I2 results in increased susceptibility to rifaximin] which results in increased expression of CD36 protein CTD PMID:22790967 NCBI chr 5:17,781,690...17,888,959
Ensembl chr 5:17,781,690...17,888,801
JBrowse link
G Cfd complement factor D (adipsin) multiple interactions ISO [NR1I2 results in increased susceptibility to rifaximin] which results in increased expression of CFD mRNA CTD PMID:22790967 NCBI chr10:79,890,853...79,892,655
Ensembl chr10:79,890,853...79,892,655
JBrowse link
G Cidec cell death-inducing DFFA-like effector c multiple interactions ISO [NR1I2 results in increased susceptibility to rifaximin] which results in increased expression of CIDEC mRNA CTD PMID:22790967 NCBI chr 6:113,424,634...113,435,760
Ensembl chr 6:113,424,634...113,435,760
JBrowse link
G Col1a1 collagen, type I, alpha 1 multiple interactions ISO [NR1I2 results in increased susceptibility to rifaximin] which results in increased expression of COL1A1 mRNA CTD PMID:22790967 NCBI chr11:94,936,224...94,953,042
Ensembl chr11:94,936,224...94,953,042
JBrowse link
G Cyp3a11 cytochrome P450, family 3, subfamily a, polypeptide 11 multiple interactions EXP
ISO
[rifaximin co-treated with Trinitrobenzenesulfonic Acid] results in increased expression of CYP3A11 mRNA
[NR1I2 results in increased susceptibility to Rifaximin] which results in increased expression of CYP3A11 mRNA
CTD PMID:21599020 PMID:22790967 NCBI chr 5:145,854,607...145,879,854
Ensembl chr 5:145,854,426...145,879,964
JBrowse link
G Cyp7a1 cytochrome P450, family 7, subfamily a, polypeptide 1 multiple interactions ISO [NR1I2 results in increased susceptibility to rifaximin] which results in increased expression of CYP7A1 protein CTD PMID:22790967 NCBI chr 4:6,265,612...6,275,632
Ensembl chr 4:6,265,612...6,275,633
JBrowse link
G Cyp7b1 cytochrome P450, family 7, subfamily b, polypeptide 1 multiple interactions ISO [NR1I2 results in increased susceptibility to rifaximin] which results in increased expression of CYP7B1 protein CTD PMID:22790967 NCBI chr 3:18,071,944...18,243,890
Ensembl chr 3:18,071,950...18,243,338
JBrowse link
G Dgat2 diacylglycerol O-acyltransferase 2 multiple interactions ISO [NR1I2 results in increased susceptibility to rifaximin] which results in increased expression of DGAT2 mRNA CTD PMID:22790967 NCBI chr 7:99,153,663...99,182,713
Ensembl chr 7:99,153,658...99,182,719
JBrowse link
G Fabp2 fatty acid binding protein 2, intestinal multiple interactions ISO [NR1I2 results in increased susceptibility to rifaximin] which results in increased expression of FABP2 protein CTD PMID:22790967 NCBI chr 3:122,895,072...122,899,506
Ensembl chr 3:122,895,072...122,899,506
JBrowse link
G Ifng interferon gamma multiple interactions EXP [rifaximin binds to and results in increased activity of NR1I2 protein] inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of IFNG protein]; rifaximin inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of IFNG protein] CTD PMID:21599020 NCBI chr10:118,441,046...118,445,894
Ensembl chr10:118,441,046...118,445,892
JBrowse link
G Il10 interleukin 10 multiple interactions EXP [rifaximin co-treated with Trinitrobenzenesulfonic Acid] results in increased expression of IL10 protein CTD PMID:21599020 NCBI chr 1:131,019,845...131,024,970
Ensembl chr 1:131,019,845...131,024,974
JBrowse link
G Lta lymphotoxin A multiple interactions ISO [NR1I2 results in increased susceptibility to rifaximin] which results in increased expression of LTA mRNA CTD PMID:22790967 NCBI chr17:35,203,165...35,205,578
Ensembl chr17:35,203,165...35,205,351
JBrowse link
G Mpo myeloperoxidase multiple interactions EXP [rifaximin binds to and results in increased activity of NR1I2 protein] inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of MPO protein]; rifaximin inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of MPO protein] CTD PMID:21599020 NCBI chr11:87,793,784...87,804,412
Ensembl chr11:87,793,581...87,804,413
JBrowse link
G Nr1h4 nuclear receptor subfamily 1, group H, member 4 multiple interactions ISO [NR1I2 results in increased susceptibility to rifaximin] which results in increased expression of NR1H4 protein CTD PMID:22790967 NCBI chr10:89,454,234...89,533,645
Ensembl chr10:89,454,234...89,533,585
JBrowse link
G Nr1i2 nuclear receptor subfamily 1, group I, member 2 multiple interactions
increases activity
increases expression
increases response to substance
ISO
EXP
4,4'-hexafluorisopropylidene diphenol inhibits the reaction [Rifaximin results in increased activity of NR1I2 protein]; 4,4'-hexafluorisopropylidene diphenol metabolite inhibits the reaction [Rifaximin results in increased activity of NR1I2 protein]; [NR1I2 results in increased susceptibility to Rifaximin] which results in increased abundance of Triglycerides; [NR1I2 results in increased susceptibility to Rifaximin] which results in increased expression of ABCB1A mRNA; [NR1I2 results in increased susceptibility to Rifaximin] which results in increased expression of ACTA2 mRNA; [NR1I2 results in increased susceptibility to Rifaximin] which results in increased expression of APOA4 mRNA; [NR1I2 results in increased susceptibility to Rifaximin] which results in increased expression of CD36 protein; [NR1I2 results in increased susceptibility to Rifaximin] which results in increased expression of CFD mRNA; [NR1I2 results in increased susceptibility to Rifaximin] which results in increased expression of CIDEC mRNA; [NR1I2 results in increased susceptibility to Rifaximin] which results in increased expression of COL1A1 mRNA; [NR1I2 results in increased susceptibility to Rifaximin] which results in increased expression of CYP3A11 mRNA; [NR1I2 results in increased susceptibility to Rifaximin] which results in increased expression of CYP7A1 protein; [NR1I2 results in increased susceptibility to Rifaximin] which results in increased expression of CYP7B1 protein; [NR1I2 results in increased susceptibility to Rifaximin] which results in increased expression of DGAT2 mRNA; [NR1I2 results in increased susceptibility to Rifaximin] which results in increased expression of FABP2 protein; [NR1I2 results in increased susceptibility to Rifaximin] which results in increased expression of LTA mRNA; [NR1I2 results in increased susceptibility to Rifaximin] which results in increased expression of NR1H4 protein; [NR1I2 results in increased susceptibility to Rifaximin] which results in increased expression of PPARG mRNA; [Rifaximin binds to and results in increased activity of NR1I2 protein] which results in decreased susceptibility to Trinitrobenzenesulfonic Acid; bis(2-ethylhexyl) 2,3,4,5-tetrabromophthalate inhibits the reaction [Rifaximin results in increased activity of NR1I2 protein]; Rifaximin binds to and results in increased activity of NR1I2 protein
[rifaximin binds to and results in increased activity of NR1I2 protein] inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of CCL3 protein]; [rifaximin binds to and results in increased activity of NR1I2 protein] inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of IFNG protein]; [rifaximin binds to and results in increased activity of NR1I2 protein] inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of MPO protein]; [rifaximin binds to and results in increased activity of NR1I2 protein] inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of TNF protein]
rifaximin results in increased expression of NR1I2 mRNA
NR1I2 results in increased susceptibility to rifaximin
CTD PMID:21599020 PMID:22291955 PMID:22790967 PMID:27506419 PMID:30408883 NCBI chr16:38,248,349...38,294,849
Ensembl chr16:38,248,323...38,294,824
JBrowse link
G Pparg peroxisome proliferator activated receptor gamma multiple interactions ISO [NR1I2 results in increased susceptibility to rifaximin] which results in increased expression of PPARG mRNA CTD PMID:22790967 NCBI chr 6:115,360,879...115,490,404
Ensembl chr 6:115,360,951...115,490,399
JBrowse link
G Tgfb1 transforming growth factor, beta 1 multiple interactions EXP [rifaximin co-treated with Trinitrobenzenesulfonic Acid] results in increased expression of TGFB1 protein CTD PMID:21599020 NCBI chr 7:25,687,002...25,705,077
Ensembl chr 7:25,687,002...25,705,077
JBrowse link
G Tnf tumor necrosis factor multiple interactions EXP [rifaximin binds to and results in increased activity of NR1I2 protein] inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of TNF protein]; rifaximin inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of TNF protein] CTD PMID:21599020 NCBI chr17:35,199,367...35,202,007
Ensembl chr17:35,199,381...35,202,007
JBrowse link

Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 21746
    role 21724
      biological role 21722
        antimicrobial agent 18356
          rifaximin 22
Path 2
Term Annotations click to browse term
  CHEBI ontology 21746
    subatomic particle 21732
      composite particle 21732
        hadron 21732
          baryon 21732
            nucleon 21732
              atomic nucleus 21732
                atom 21732
                  main group element atom 21647
                    p-block element atom 21647
                      carbon group element atom 21454
                        carbon atom 21353
                          organic molecular entity 21353
                            organic group 19931
                              organic divalent group 19918
                                organodiyl group 19918
                                  carbonyl group 19903
                                    carbonyl compound 19903
                                      carboxylic acid 19223
                                        carboacyl group 17998
                                          univalent carboacyl group 17998
                                            carbamoyl group 17763
                                              carboxamide 17763
                                                lactam 8088
                                                  ansamycin 856
                                                    rifamycins 409
                                                      rifaximin 22
paths to the root